A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients

Inclusion Criteria: * FIGO stage: ⅠB～ⅡA, cervical cancer; * Age≤60 years; female, Chinese women; * Initial treatment is radical hysterectomy + pelvic lymph node dissection; * Pathological diagnosis: cervical squamous cell invasive carcinoma; * Pathologic examination and meet the following one of the indications of adjuvant therapy: ① lymph node metastasis, ② parametrial invasion, ③ ≥ 2/3 deep stromal invasion, ④ histopathological grading in poorly differentiated (G2 to G3), ⑤ lymphatic vascular space involvement, ⑥ tumor diameter\> 4cm; * Laboratory tests: WBC≥4×10(9)/L, NEU≥2×10(9)/L, PLT≥80×10(9)/L, serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal, BUN, Cr≤ normal * Performance status: Karnofsky score≥60; * No prior treatment; * Receiving extensive resection of uterus (type III) plus pelvic lymph nodes wide resection; pathologically diagnosed with cervical squamous cell carcinoma; * Provide written informed consent. Exclusion Criteria: * With severe or uncontrolled internal disease, unable to receive surgery and/or unsuitable for radiotherapy or chemotherapy * History of organ transplantation, immune diseases; * History of serious mental illness, a history of brain dysfunction; * Drug abuse or a history of drug abuse; * Suffering from other malignancies; * Concurrently participating in other clinical trials * Unable or unwilling to sign informed consents; * Unable or unwilling to abide by protocol.